chr11-118168704-C-T
Variant summary
Our verdict is Likely benign. The variant received -6 ACMG points: 0P and 6B. BP4_ModerateBS2
The NM_004588.5(SCN2B):c.118G>A(p.Val40Ile) variant causes a missense change. The variant allele was found at a frequency of 0.0000731 in 1,614,088 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_004588.5 missense
Scores
Clinical Significance
Conservation
Publications
- atrial fibrillation, familial, 14Inheritance: AD, Unknown Classification: MODERATE, LIMITED Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae)
- Brugada syndromeInheritance: AD Classification: SUPPORTIVE, LIMITED Submitted by: Orphanet, Genomics England PanelApp
- familial atrial fibrillationInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Brugada syndrome 1Inheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -6 ACMG points.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| SCN2B | ENST00000278947.6 | c.118G>A | p.Val40Ile | missense_variant | Exon 2 of 4 | 1 | NM_004588.5 | ENSP00000278947.5 | ||
| SCN2B | ENST00000658882.1 | n.222G>A | non_coding_transcript_exon_variant | Exon 3 of 5 | ENSP00000499572.1 | |||||
| SCN2B | ENST00000665446.1 | n.354G>A | non_coding_transcript_exon_variant | Exon 3 of 4 | ||||||
| SCN2B | ENST00000669850.1 | n.360G>A | non_coding_transcript_exon_variant | Exon 2 of 4 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152202Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000477 AC: 12AN: 251472 AF XY: 0.0000589 show subpopulations
GnomAD4 exome AF: 0.0000780 AC: 114AN: 1461886Hom.: 0 Cov.: 32 AF XY: 0.0000811 AC XY: 59AN XY: 727244 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152202Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74358 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Atrial fibrillation, familial, 14 Uncertain:1
This sequence change replaces valine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 40 of the SCN2B protein (p.Val40Ile). This variant is present in population databases (rs200761835, gnomAD 0.01%). This missense change has been observed in individual(s) with clinical features of Brugada syndrome (PMID: 26220970). ClinVar contains an entry for this variant (Variation ID: 191494). An algorithm developed to predict the effect of missense changes on protein structure and function outputs the following: PolyPhen-2: "Benign". The isoleucine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
not provided Uncertain:1
- -
Cardiovascular phenotype Uncertain:1
The p.V40I variant (also known as c.118G>A), located in coding exon 2 of the SCN2B gene, results from a G to A substitution at nucleotide position 118. The valine at codon 40 is replaced by isoleucine, an amino acid with highly similar properties. This variant co-occurred with variants in other cardiac-related genes in an individual from a Brugada syndrome cohort, and has been reported as a secondary cardiac variant in an exome cohort; however, details were limited (Di Resta C et al. Hum Mol Genet, 2015 Oct;24:5828-35; Ng D et al. Circ Cardiovasc Genet, 2013 Aug;6:337-46). This amino acid position is not well conserved in available vertebrate species, and isoleucine is the reference amino acid in other vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at